Patients Discontinuing Weight-Loss Injections Regain Pounds Four Times Faster Than People Using Diet and Exercise

A recent study indicates that patients who come off new weight-loss injections like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who end traditional lifestyle regimens.

Published data in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping.

"People using such medications must be cognizant of the danger of fast weight regain when the treatment ends," warns expert Dr. Susan Jebb.

That rate of recovery implies a reversion to pre-treatment mass in about a year and a half.

Weighing Therapies

The study, which looked at 37 of trials involving thousands of participants, compared the results of the injectable medications with other pills.

Scientists note that people who lose weight through lifestyle changes alone generally experience a less rapid weight regain—perhaps 100 grams monthly—once they finish.

Explaining the Rapid Rebound

Experts believe the mechanism of the jabs accounts for the amplified weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Long-term administration of the hormone concentrations far above than normal could lead to the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating far more likely."

An Ongoing Condition?

Health authorities suggest the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.

A number of clinicians contend that, due to the likelihood of relapse, the treatment is often ongoing.

This perspective is supported by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," similar to managing conditions like hypertension.

Patient Accounts

People who have come off the medication describe a intense resurgence of hunger.

"It felt as if a trigger that goes on and you become ravenous," said one woman.

This difficulty is worsened if users have not adopted lasting dietary or behavioural modifications during treatment.

Growing Adoption

Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.

• Adoption is more common among women compared to males.
• The middle-aged demographic shows the highest level of interest.
• Many access the medications through private prescriptions rather than the NHS.

In conclusion, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone fix and lasting health benefits hinges on ongoing lifestyle changes.